Hypertrophic Cardiomyopathy Treatment Agents, Ablative

"Hypertrophic Cardiomyopathy Treatment Agents, Ablative" is a specialized formulary classification rather than a broad, standard pharmacologic drug class It specifically designates procedural chemical ablation agents—principally dehydrated alcohol (such as FDA-approved Ablysinol)—administered via targeted intra-arterial catheterization into a septal perforator coronary artery

"Hypertrophic Cardiomyopathy Treatment Agents, Ablative" is a specialized formulary classification rather than a broad, standard pharmacologic drug class

It specifically designates procedural chemical ablation agents—principally dehydrated alcohol (such as FDA-approved Ablysinol)—administered via targeted intra-arterial catheterization into a septal perforator coronary artery The principal mechanism of action is the induction of localized, controlled myocardial infarction and coagulative necrosis within the hypertrophied basal interventricular septum This targeted tissue ablation thins the cardiac septum to reduce dynamic left ventricular outflow...

This targeted tissue ablation thins the cardiac septum to reduce dynamic left ventricular outflow tract obstruction, and its therapeutic role is specifically indicated to improve functional capacity and alleviate symptoms in patients with severe, drug-refractory symptomatic obstructive hypertrophic cardiomyopathy who are not optimal candidates for surgical septal myectomy